scholarly journals Cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Hector Lafuente ◽  
Ibon Jaunarena ◽  
Eukene Ansuategui ◽  
Arantza Lekuona ◽  
Ander Izeta
Keyword(s):  
Systematic Review ◽  
Clinical Studies ◽  
Meta Analysis ◽  
Cell Types ◽  
Lymphatic Drainage ◽  
Secondary Lymphedema ◽  
Disease Outcomes ◽  
Underlying Mechanisms ◽  
Preclinical And Clinical Studies ◽  
Positive Effect

Abstract Background Lymphedema, the accumulation of interstitial fluid caused by poor lymphatic drainage, is a progressive and permanent disease with no curative treatment. Several studies have evaluated cell-based therapies in secondary lymphedema, but no meta-analysis has been performed to assess their efficacy. Methods We conducted a systematic review and meta-analysis of all available preclinical and clinical studies, with assessment of their quality and risk of bias. Results A total of 20 articles using diverse cell types were selected for analysis, including six clinical trials and 14 pre-clinical studies in three species. The meta-analysis showed a positive effect of cell-based therapies on relevant disease outcomes (quantification of edema, density of lymphatic capillaries, evaluation of the lymphatic flow, and tissue fibrosis). No significant publication bias was observed. Conclusion Cell-based therapies have the potential to improve secondary lymphedema. The underlying mechanisms remain unclear. Due to relevant heterogeneity between studies, further randomized controlled and blinded studies are required to substantiate the use of these novel therapies in clinical practice.

Tissue Engineering of the Urethra: A Systematic Review and Meta-analysis of Preclinical and Clinical Studies

2017 ◽  
Vol 72 (4) ◽  
pp. 594-606 ◽  
Author(s):  
Luuk R.M. Versteegden ◽  
Paul K.J.D. de Jonge ◽  
Joanna IntHout ◽  
Toin H. van Kuppevelt ◽  
Egbert Oosterwijk ◽  
...  
Keyword(s):  
Systematic Review ◽  
Tissue Engineering ◽  
Clinical Studies ◽  
Meta Analysis ◽  
Preclinical And Clinical Studies

scholarly journals Platelet-Rich Plasma for Bone Fracture Treatment: A Systematic Review of Current Evidence in Preclinical and Clinical Studies

2021 ◽  
Vol 8 ◽  
Author(s):  
Yangming Zhang ◽  
Fei Xing ◽  
Rong Luo ◽  
Xin Duan
Keyword(s):  
Systematic Review ◽  
Bone Fracture ◽  
Clinical Studies ◽  
Platelet Rich Plasma ◽  
Fracture Treatment ◽  
Preclinical Studies ◽  
Preclinical And Clinical Studies ◽  
Positive Effect ◽  
Present Systematic Review

Background: Recently, there is an increasing interest in the therapeutic potential of platelet-rich plasma (PRP) for bone fracture treatment. Nevertheless, the effect of PRP for bone fracture treatment remains controversial and is still a matter of discussion. Therefore, we performed a systematic review to evaluate the efficacy and safety of PRP injection for treatment of bone fracture.Methods: The main bibliographic databases, including Medline, PubMed, Embase, Web of Science, and the Cochrane library, were comprehensively searched for studies focusing on the application of platelet-rich plasma (PRP) on bone fracture treatment. All relevant articles were screened for eligibility and subdivided into the preclinical and clinical studies. Data were extracted and presented systematically.Results: Finally, twenty-six in vitro preclinical studies (basic studies), nine in vivo preclinical studies (animal studies), and nine clinical studies, met the selection criteria, and were included in the present systematic review. Preclinical studies showed an overall positive effect of PRP on osteoblast-like cells in vitro and bone healing in animal models. The most used treatment for bone fracture in animal and clinical studies is fixation surgery combined with PRP injection. The clinical studies reported PRP shortened bony healing duration, and had no positive effect on improving the healing rate of closed fractures. However, the results of functional outcomes are controversial. Additionally, compared with control group, PRP would not increase the rate of postoperative wound infection.Conclusion: The present systematic review confirmed the continuing interests of PRP as an additional treatment for bone fracture. Preclinical studies highlighted the potential value of PRP as promising therapy for bone fracture. However, the preclinical evidence did not translate into a similar result in the clinical studies. In addition, types of fractures and procedures of PRP preparation are heterogeneous in enrolled studies, which might result in controversial results. Meanwhile, characteristics of PRP, such as platelet concentration, the numbers of leukocytes, still need to be determined and further research is required.

scholarly journals PLATELET-RICH PLASMA THERAPY FOR ERECTILE DYSFUNCTION: A REVIEW OF PRECLINICAL AND CLINICAL STUDIES

2019 ◽  
Vol 6 (3) ◽  
pp. 74-86
Author(s):  
A. D. Kaprin ◽  
A. A. Kostin ◽  
M. V. Epifanova ◽  
M. E. Chalyy ◽  
E. V. Gameeva ◽  
...  
Keyword(s):  
Systematic Review ◽  
Erectile Dysfunction ◽  
Clinical Studies ◽  
Platelet Rich Plasma ◽  
Meta Analysis ◽  
Current Data ◽  
Cochrane Library ◽  
Multicenter Studies ◽  
Plasma Therapy ◽  
Preclinical And Clinical Studies

Erectile dysfunction is no longer a psychosocial problem. Nowadays, it is a marker specific for the initial stages of cardiovascular diseases. Рlatelet-rich plasma (PRP) is a new and promising method, which totally deserves to be noted by specialists. To review currently existing pre-clinical and clinical studies concerning application of PRP in erectile dysfunction published in international sources such as PubMed, Cochrane Library, Clinicaltrials.gov. The current data of preclinical and clinical studies determine the absence of PRP side effects and the effectiveness for ED treatment. PRP-therapy is a pathogenetically substantiated method of treating erectile dysfunction. The therapy is designed for repair and regeneration of endothelium, smooth muscle cells, and connective tissue. However, large, placebo-controlled, multicenter studies are needed to creation a systematic review and meta-analysis.

EXPRESS: Therapeutic Hypothermia for Intracerebral Hemorrhage: Systematic Review and Meta-Analysis of the Experimental and Clinical Literature

2021 ◽  
pp. 174749302110448
Author(s):  
Turner Baker ◽  
John Durbin ◽  
Zachary Troiani ◽  
Luis Ascanio-Cortez ◽  
Rebecca Baron ◽  
...  
Keyword(s):  
Systematic Review ◽  
Intracerebral Hemorrhage ◽  
Therapeutic Hypothermia ◽  
Cerebral Edema ◽  
Clinical Studies ◽  
Meta Analysis ◽  
Tissue Loss ◽  
Hematoma Expansion ◽  
Preclinical Studies ◽  
Preclinical And Clinical Studies

Background Intracerebral hemorrhage (ICH) remains the deadliest form of stroke worldwide, inducing neuronal death through a wide variety of pathways. Therapeutic hypothermia (TH) is a robust and well studied neuroprotectant widely used across a variety of specialties. Aims This review summarizes results from preclinical and clinical studies to highlight the overall effectiveness of TH to improve long-term ICH outcomes while also elucidating optimal protocol regimens to maximize therapeutic effect. Summary of Review A systematic review was conducted across three databases to identify trials investigating the use of TH to treat ICH. A random-effects meta-analysis was conducted on preclinical studies, looking at neurobehavioral outcomes, blood brain barrier breakdown (BBB), cerebral edema, hematoma volume, and tissue loss. Several mixed-methods meta-regression models were also performed to adjust for variance and variations in hypothermia induction procedures. 21 preclinical studies and 5 human studies were identified. The meta-analysis of preclinical studies demonstrated a significant benefit in behavioral scores (ES=-0.43, p=0.02), cerebral edema (ES=1.32, p=0.0001), and BBB (ES=2.73, p=<0.00001). TH was not found to significantly affect hematoma expansion (ES=-0.24, p=0.12) or tissue loss (ES=0.06, p=0.68). Clinical study outcome reporting was heterogeneous, however there was recurring evidence of TH-induced edema reduction. Conclusions The combined preclinical evidence demonstrates that TH reduced multiple cell death mechanisms initiated by ICH, yet there is no definitive evidence in clinical studies. The cooling strategies employed in both preclinical and clinical studies were highly diverse, and focused refinement of cooling protocols should be developed in future preclinical studies. The current data for TH in ICH remains questionable despite the highly promising indications in preclinical studies. Definitive randomized controlled studies are still required to answer this therapeutic question.

Sign in / Sign up

Export Citation Format

Share Document